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http://dx.doi.org/10.1016/j.jmii.2015
1684-1182/Copyright ª 2015, TaiwanAbstract Background: Antimicrobial susceptibility and prevalence of pediatric urinary tract
infection (UTI) is very useful for pediatricians in selecting effective antibiotics in time to
improve outcomes in patients. This study aimed to determine the prevalence rate, bacterial
distribution, and antimicrobial susceptibility of UTI in febrile young children at a teaching hos-
pital in northern Taiwan.
Methods: From January 2011 to December 2011, all urinary isolates from suspected cases of
UTI in febrile young children aged from 1 day to 36 months visiting the Pediatric Emergency
Room of Chang Gung Children’s Hospital, Taoyuan, Taiwan were identified by conventional
methods. Antibiotic susceptibility was determined according to the Clinical and Laboratory
Standards Institute.
Results: A total of 5470 (78%) from 7009 eligible children were enrolled in the study, and 619
(11.3%) had a diagnosis of UTI. The most prevalent bacterium was Escherichia coli (68%) fol-
lowed by Klebsiella pneumoniae (8.1%) and Proteus mirabilis (6.8%). Ampicillin, piperacillin,
and trimethoprim-sulfamethoxazole (TMP-SMX) showed a higher resistance rate in the three
predominant bacteria. All tested bacteria showed higher resistance to ampicillin (79.3%) and
TMP-SMX (44.1%), and lower resistance to cefazolin (17.7%) and gentamicin (13.0%). Fourteenof Pediatrics, Chang Gung Children’s Hospital, Chang Gung University College of Medicine, Number 5
an, Taiwan.
.org.tw (C.-H. Chiu).
.05.016
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244 C.-T. Wu et al.percent of the isolates produced extended spectrum b-lactamase (ESBL), among which 93.33%
were E. coli isolates.
Conclusion: The overall prevalence of UTI in this study was higher than previously reported in
febrile children. Higher antimicrobial resistance was found in ampicillin and TMP-SMX. Among
commonly used antibiotics, cefazolin and gentamicin are recommended to treat UTI in febrile
children aged < 3 years without localizing signs.
Copyright ª 2015, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
The true incidence of urinary tract infection (UTI) in febrile
young children ( 3 years old) is difficult to estimate,
particularly because those with UTI may only have fever
without specific symptoms or signs.
UTI is a common cause of fever and a frequent reason for
referral to the emergency department and hospitalization,
particularly in infancy.1 UTI is present in w1.8e13.6% of
febrile infants and inw2e4.5% of febrile children aged < 5
years.2e8 However, the prevalence rate of UTI in young
children in Taiwan has never been reported.
UTI may present no urinary symptom or sign, and a delay
in diagnosis and treatment may occur. In infants and young
children aged < 3 years with unexplained fever, the degree
of toxicity, dehydration, and ability to retain oral intake
must be assessed carefully. The prognosis is usually favor-
able, but relies on timely administration of appropriate
initial antimicrobial treatment.8,9 Appropriate treatment
requires information regarding the susceptibility patterns
of the current bacteria in order to give effective antibiotics
in time.8e10 Although current antibiotic susceptibility of
Escherichia coli has been reported,11 no additional data are
available regarding the overall uropathogens and their
antibiotic susceptibilities. How to select effective antibi-
otics for treating current UTIs still remains unknown.
The present study was performed to determine the
prevalence rate of UTI in patients aged < 3 years and the
uropathogens in the emergency room of a tertiary pediatric
medical center, examine their antibiotic susceptibility, and
determine the appropriateness of the empirical antibiotics
used.Materials and methods
Study design
The study population consisted of patients attending the
pediatric emergency department (PED) at a university
teaching children’s hospital in northern Taiwan between
January 2011 and December 2011. A retrospective elec-
tronic chart review of medical records was performed. All
infants aged  3 years presenting with fever (rectal
temperatures  38C by history or in the PED) were eligible
for enrollment in the study. Infants were excluded if they
had received antibiotics within 48 hours of PED presenta-
tion or if they had a definite source of fever onexamination. Clinical and laboratory data of all enrolled
children were collected retrospectively from the electronic
medical records. We recorded data on sex, age, underlying
disorders, previous hospitalizations, previous antibiotic
use, and results of urine culture.Ethics statement
The project was reviewed and approved by the Institutional
Review Board (IRB) of Chang Gung Memorial Hospital,
Taoyuan, Taiwan (IRB No. 102-0498B).Inclusion criteria
Patients with positive urinary cultures were included. The
method of urine sample collection for urine culture was
clean-catch urine collection using a bag after thorough skin
sterilization.12e14 A good correlation has been proved be-
tween the results of a urine culture obtained using this
method and by suprapubic bladder aspiration.15 A positive
culture was defined as follows: growth of a single urinary
tract pathogen with at least > 105 colony-forming units
(CFU)/mL in urine specimens.11e16 Patients with underlying
renal disease, recurrent UTI, or contamination were
excluded.Antibiotic susceptibility testing
Antibiotic susceptibility was determined using standard
techniques.17 Isolates in the “intermediate” category were
deemed “resistant” in this study. Antimicrobial suscepti-
bility was determined using the disk diffusion method ac-
cording to Clinical and Laboratory Standards Institute (CLSI)
standards.18 Extended spectrum b-lactamase (ESBL)-pro-
ducing organisms were screened and confirmed according
to the method suggested by the CLSI.18Statistical analysis
Data were recorded and entered into a database. Analyses
were performed using SPSS software, version 17.0 (SPSS
Inc., Chicago, IL, USA). The Student t test, the Chi-square
test, or Fisher exact test was used when appropriate to
compare proportions. All statistical analyses were two-
sided, and significance was set at p < 0.05.
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Over the study period from January 1, 2011 to December
31, 2011, a total of 19,818 patients aged < 3 years visited
the PED, and 7009 children fulfilled the criteria of fever.
However, 1539 children were excluded due to having
received antibiotic agents or the identification of any other
reasons for fever in addition to UTI. Urine samples were
collected from 5470 febrile children. A total of 619 patients
whose urine samples met the definition of positive urine
culture were finally enrolled in the study.
Table 1 compares prevalence among patients of
different sex and age, including those aged < 1 year, be-
tween 1 year and 2 years, and between 2 years and 3 years.
The mean age of the whole study group was 9.3  8.3
months old. Overall prevalence in febrile patients aged < 3
years was 11.3%. Prevalence of febrile patients aged < 1
year (12.3%) was significantly higher than that of febrile
patients aged 2e3 years (10%) and 1e2 years (8%;
p < 0.001). In febrile patients aged < 1 year, boys had
significant higher prevalence (14%) than girls (10.6%;
p Z 0.004). By contrast, girls had significant higher prev-
alence than boys in febrile patients aged 1e2 years
(p Z 0.001) and 2e3 years (p Z 0.005).
The microorganisms were isolated in the 619 episodes of
UTI in children. E. coli (68%), Klebsiella pneumoniae (8.1%),
Proteus mirabilis (6.8%), and Enterobacter faecalis (4%)
infection were the most prevalent bacteria in our patients.
Twelve infections (2%) were caused by Pseudomonas aeru-
ginosa. E. coli accounted forw73.5% of cases in the 1-year-
old age group, which was significantly higher than the in-
cidences in the other age groups (p Z 0.001). The fre-
quencies of K. pneumoniae and P. mirabilis increased by
not less than 1.4e2.8-fold in the 1e2-year-old and 2e3-
year-old groups, respectively. The frequency and distribu-
tion of the different microorganisms are summarized in
Table 2.
Table 3 shows the resistance of the three predominant
pathogens to various antimicrobial agents. More than 70% of
E. coli, K. pneumonia, and P. mirabilis were susceptible to
most antibiotics, including cephalosporines (cefazolin,
cefuroxime, ceftriaxone, and ceftazidime), aminoglyco-
sides (gentamicin and amikacin), piperacillin-tazobactam
(Tazocin), ciprofloxacin, and imipenem.
Among the antibiotics, amikacin and imipenem showed
the widest coverage against E. coli isolates (100%), fol-
lowed by Tazocin (98.6%). Moreover, the fluoroquinolones
showed high potency against E. coli (91%). KlebsiellaTable 1 Comparison of prevalence of urinary tract infection am
Age (y) Male
No./total (%)
Female
No./total (%
<1 269/1956 (14) 199/1863 (1
1e2 43/679 (6.3) 58/495 (11.
2e3 19/271 (7) 31/206 (15)
P (among age) <0.001 0.158
Overall 331/2906 (11.4) 288/2564 (1isolates showed high susceptibility to imipenem (100%)
followed by fluoroquinolones (98%), amikacin (94%), cefta-
zidime (92%), and ceftriaxone (92%). Among the b-lactam
antibiotics, imipenem showed the widest coverage against
Gram-negative isolates (100%). This was followed by ami-
kacin and ciprofloxacin.
However, three antibiotics were more resistant to E.
coli: 82.9% of the strains were resistant to ampicillin, 77.9%
to piperacillin, and 48% to trimethoprim-sulfamethoxazole
(TMP-SMX). Four antibiotics were more resistant to K.
pneumonia: 98% of strains were resistant to ampicillin, 44%
to piperacillin, 26% to cefazolin, and 22% to TMP-SMX. Two
antibiotics were more resistant to P. mirabilis: 67% of
strains were resistant to ampicillin and 38.1% to TMP-SMX.
Resistance to third-generation cephalosporins was mostly
due to the presence of ESBL. ESBLs were found in 15 pa-
tients (E. coli, n Z 14; K. pneumoniae, n Z 1).
Table 4 shows resistance of the four most commonly
used antibiotics for treating UTIs in the three age groups.
More than 40% resistance to ampicillin and TMP-SMX was
found in the data of all age groups. A higher rate of resis-
tance to ampicillin was found in data of the 2e3-year-old
group than in that of the < 1-year-old group (p Z 0.035).
Resistance to cefazolin and gentamicin were significantly
lower in data of the < 1-year-old group compared with that
of the 1e2-year-old group (cefazolin: p < 0.001, genta-
micin: pZ0.038).Discussion
UTI is present in approximately 1.8e13.6% of febrile infants
and w2e4.5% of febrile children aged < 5 years.2e4 The
overall rate of UTI observed in this study was 11.3% in
febrile children aged < 3 years. Higher rates in the younger
age groups are seen in our study. An important difference is
the high proportion of uncircumcised boys in Taiwan. In a
recent Taiwanese study, the observed rate of UTI was 19%
among 94 febrile uncircumcised male infants aged < 8
weeks.19 In this study, the prevalence rates of UTI in girls
aged < 1 year (10.6%) and between 1 year and 2 years
(11.7%), and in boys aged < 1 year (14%) were higher than
those in other reports (6.5%, 8.1%, and 3.3%, respec-
tively).20,21 This latter difference may have been due to the
lower rate of circumcised boys in Taiwan compared with
the United States. Wiswell and Roscelli22 reported a 10-fold
increase in the incidence of UTI in uncircumcised compared
with circumcised male infants during the 1st year of life. If
young children with suspected UTI are assessed as toxic,ong children of different age and sex
)
p
(male vs. female)
Total
No./total (%)
0.6) 0.004 468/3819 (12.3)
7) 0.001 101/1274 (8)
0.005 50/477 (10)
<0.001
1.2) 0.854 619/5470 (11.3)
Table 2 Comparison of bacteria isolated from patients with urinary tract infection in different age groups
Bacteria Age group p
< 1 y 1e2 y 2e3 y
Escherichia coli 344 (73.5) 52 (51.4) 25 (50) 421 (68) 0.001
Klebsiella pneumoniae 33 (7) 10 (9.9) 7 (14) 50 (8) NS
Proteus mirabilis 25 (5.3) 10 (9.9) 7 (14) 42 (6.8) NS
Enterococcus faecalis 17 (3.6) 5 (5) 1 (2) 23 (4) NS
Morganella morganii 6 (1.3) 10 (9.9) 3 (6) 19 (3) NS
Citrobacter species 11 (2.4) 3 (3) 1 (2) 15 (2) NS
Escherichia coli ESBL 11 (2.4) 2 (2) 1 (2) 14 (2) NS
Pseudomonas aeruginosa 4 (0.9) 4 (4) 4 (8) 12 (2) NS
GBS 9 (1.9) 3 (3) 0 12 (2) NS
Yeast 4 (0.9) 1 (1) 0 5 (0.8) NS
Enterobacter cloacae 3 (0.6) 1 (1) 1 (2) 5 (1) NS
Klebsiella pneumoniae ESBL 1 (0.2) 0 0 1 (0.2) NS
Total 468 (75.6) 101 (16.3) 50 (8.1) 619
Data are presented as n (%).
ESBL Z extended spectrum b-lactamase; GBS Z group B Streptococci ; NS Z nonsignificant.
246 C.-T. Wu et al.dehydrated, or unable to retain oral intake, initial antimi-
crobial therapy should be administered parenterally and
hospitalization should be considered. Therefore, studies to
increase our knowledge about the types of pathogen
responsible for UTIs and their resistance patterns to anti-
biotic drugs are very important to help clinicians choose the
appropriate empirical treatment.23
The results of the present study indicated the antibiotic
susceptibility of uropathogen isolates responsible for UTI in
different age groups of young children. UTIs are one of the
most common types of bacterial infection encountered by
both general practitioners and hospital doctors. Infants and
children aged < 3 years with unexplained fever are cause
for particular concern. UTI may cause few recognizable
signs or symptoms other than fever, and has a greater po-
tential for renal damage than in older children.21
This study shows the distribution and antibiotic suscep-
tibility of microbial species isolated from infants andTable 3 Antimicrobial resistance of the three predominant urin
Escherichia coli
N Z 421
Kl
No. Resistance (%) No.
Ampicillin 349 82.9 49
Gentamicin 59 14 7
Cefazolin 67 15.9 13
Piperacillin 328 77.9 22
TMP-SMX 203 48.2 11
Amikacin 0 0 3
Ciprofloxacin 38 9 1
Cefuroxime 25 5.9 4
Tazocin 6 1.4 4
Ceftriaxone 23 5.5 4
Ceftazidime 19 4.5 4
Imipenem 0 0 0
TMP-SMX Z trimethoprim-sulfamethoxazole.children aged < 3 years with community-acquired UTIs in a
population in northern Taiwan. This study provided valu-
able laboratory data and allowed comparison of the situa-
tion in Taiwan with that in other countries. In the present
study, E. coli was the most common pathogen isolated,
which corresponds to the data obtained in other stud-
ies.23e27 K. pneumoniae and P. mirabilis were the second
and third most common pathogens, with rates of 8.3% and
7%, respectively. In the present study, only 12 infections
(1.9%) were caused by P. aeruginosa, which was signifi-
cantly lower than the rates in other reports (2.9e8%).28e31
The main differences between our results and those of
studies conducted in Western countries were the resistance
patterns of E. coli. E. coli and Klebsiella isolates in our
study showed different resistance rates to ampicillin (82.9%
and 98%, respectively), whereas for TMP-SMX and piper-
acillin, E. coli were more resistant (48% and 78%, respec-
tively) than K. pneumoniae (22% and 44%, respectively) inary pathogens
ebsiella pneumoniae
N Z 50
Proteus mirabilis
N Z 42
Resistance (%) No. Resistance (%)
98 28 67
14 6 14.3
26 6 14.3
44 7 16.7
22 16 38.1
6 0 0
2 1 2.4
8 2 4.8
8 0 0
8 0 0
8 0 0
0 0 0
Table 4 Comparison of resistance to the four most common antimicrobial agents for treating urinary tract infections among
different age groups
< 1 y 1e2 y 2e3 y p (among the 3 age groups)  3 y
Ampicillin 355/455 (78.0) 75/94 (79.8) 42/46 (91.3) 0.105 472/645 (79.3)
Cefazolin 59/410 (14.4) 26/80 (32.5) 9/40 (22.5) <0.001 94/530 (17.7)
Gentamicin 48/427 (11.2) 17/88 (19.3) 8/47 (17.0) 0.084 73/562 (13.0)
TMP-SMX 177/424 (41.7) 46/85 (54.1) 21/44 (47.7) 0.352 244/553 (44.1)
Data are presented as n/N (%).
TMP-SMX Z trimethoprim-sulfamethoxazole.
Urinary tract infection in febrile young children 247this study. Rates of resistance to ampicillin are high in E.
coli (82.9%), K. pneumoniae (98%), and P. mirabilis (67%).
The resistance rates to ampicillin increased in comparison
to previous analyses.29e31 Pape et al31 reported 100 chil-
dren with community UTI. The resistance rates to ampicillin
were 69% in E. coli. Ladhani and Gransden29 studied 1774
children with UTI and reported rates of resistance to
ampicillin in E. coli (51.1%), K. pneumoniae (100%), and P.
mirabilis (15.2%). The extensive use of these drugs explains
the high selection pressure for resistant bacteria. Our rate
of uropathogens resistant to TMP-SMX (44.1%) was higher
than anticipated. Allen et al32 reported a rate of resistance
to TMP-SMX of 31% in children (inpatients and outpatients).
In this study, the rate of TMP-SMX resistance in E. coli was
48.2% lower than reported previously by Wu et al.33 How-
ever, the resistance rate increased in the older age group.
Furthermore, E. coli showed increases in resistance rate to
third-generation cephalosporins in Taiwan. ESBLs were
found in 15 patients (E. coli, n Z 14; K. pneumoniae,
n Z 1). Of our E. coli isolates, 3.2% were ESBL producers,
followed by 1.9% of K. pneumoniae. The high level of
multidrug resistance may have been due to the production
of ESBLs by these isolates.23,34e36
The initial choice of antibacterial therapy is based on
knowledge of the predominant pathogen in the patient’s
age group, antibacterial sensitivity patterns in the practice
area, the clinical status of the patient, and the opportunity
for close follow up. The use of an inappropriate antibiotic
will delay effective treatment and increase the risks of
urosepsis and renal scarring.21 The current American
Academy of Pediatrics guideline for management of UTIs in
febrile infants and young children suggests to give oral or
parenteral (then changed to oral) antibiotics for 7e14
days.16 Ceftriaxone, cefotaxime, ceftazidime, gentamicin,
tobramycin, and piperacillin were drugs of choice for
parenteral therapy.16 By contrast, amoxicillin-clavulanate,
sulfonamide (trimethoprim-sulfamethoxazole or sulfisox-
azole), or cephalosporin (cefixime, cefpodoxime, cefprozil,
cefuroxime axetil, or cephalexin) was recommended as an
oral agent for treating UTI.16 In Taiwan, use of ampicillin
and TMP-SMX as a single agent for empirical treatment of a
suspected UTI would not cover the majority of urinary
pathogens according to this study. Amikacin is suitable in all
age groups. Cefazolin and gentamicin are effective thera-
peutic agents for pediatric UTIs,33 and are recommended as
a first-line therapy in cases of uncomplicated UTI. We found
lower resistance rates to cefazolin and gentamicin in UTI in
the < 1-year-old group. The resistance rate increased in the
older age groups. The third generation cephalosporinshould be reserved for serious or critical cases to prevent
bacterial resistance. Our results also indicated that the
resistance rate of ampicillin was higher in the 2e3-year-old
group. Pediatric doctors must be aware of the resistance
patterns of uropathogens in their practice area and pre-
scribe empirical antibiotics. The increasing rates of resis-
tance of E coli to ampicillin, piperacillin, and TMP-SMX limit
their use in symptomatic UTI.
In conclusion, regional and demographic differences in
the susceptibility patterns of urinary pathogens mandate
local, population-specific surveillance to choose the
appropriate empirical pharmacotherapy for UTIs in chil-
dren. We suggest that empirical antibiotic selection should
be done based on local prevalence of bacterial organisms
and antibiotic sensitivities rather than on universal guide-
lines. This study revealed increasing resistance rates of E.
coli and production of ESBL among patients with UTI aged
< 3 years. Although cefazolin and gentamicin remain good
choices for most patients in our community, we should
identify those pediatric patients in the emergency depart-
ment who are at increased risk of infection with resistant
pathogens and require an alternative antibiotic. This study
will be useful for pediatric doctors in Taiwan to improve
appropriate empirical treatment.Conflicts of interest
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